U.S. Markets open in 9 hrs 18 mins

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
93.33+5.18 (+5.88%)
At close: 4:00PM EST
Sign in to post a message.
  • S
    Took profited. It’s coming in too hot right now. I will watch and try and get back in cheaper.
  • c
    told you this is heading to over $100...thumbs down person with your all your fake aliases ...
  • H
    on to $100
  • b
    28x TTM revenue?
  • Y
    Yahoo Finance Insights
    CareDx reached an all time high at 90.94
  • Y
    Yahoo Finance Insights
    CareDx reached an all time high at 85.99
  • Y
    Yahoo Finance Insights
    CareDx reached an all time high at 89.71
  • c
    5 weeks ago I said on to $60...hit it today!! now on to $70....let's go!! bought it at $1.18 7/24/17....
  • Y
    Yahoo Finance Insights
    CareDx reached an all time high at 84.17
  • J
    Simply... Worth repeating from previous post...Great Conference...AlloSure > 2 Billion Dollar market > 65% margin...GLTA...

    Efficient Commercial Launch
    Concentrated Call Points
    265 Tertiary Care Centers
    100 centers account for 80% of kidney transplants
    Broad reimbursement at Launch
    80% of patients covered by Medicare
    Leverage Existing AlloMap Infrastructure
    Core laboratory, reimbursement, G&A infrastructure in place
    Leverage Existing Commercial Channel
    Commercial presence in major transplant centers
    Field Team and Marketing already in place
    Significant Pre-Launch Commercialization Activity
    Strong foundation for rapid adoption and growth
    *Medicare Rate
    Source: Company estimates
    18,000 Kidney Transplants
    265 Centers
    (100 centers = 80% transplants)
    Year 1: 7 AlloSure tests, 4/year
    > $2 Bn
    >> opportunity (in launch)
    AlloMap provides commercial platform
    Transplant per Year 2,600 Heart Transplants
    Targets 130 Centers
    (50 centers = 70% transplants)
    Testing Frequency Year 1: 6-8 tests, 2-4/year
    Addressable Market $100 M
    Revenue > $30 M (current run-rate)
    Reimbursement/Test* $2,840 → $3,240
    Gross Margin ≈65%
  • r
    Any experts comment on today's short report and share drop? How much truth or bias in it?

    Sahm Adrangi's Kerrisdale Capital Issues Negative Report on CareDx, Inc. and Announces Conference Call Schedule
  • J
    Just the facts>>>>>>>>>>2 billion...No competition in a 2 billion dollar market...During the third quarter, the CareDx team achieved several important milestones with respect to AlloSure. As a reminder, AlloSure measures donor-derived cell-free DNA to detect active organ rejection. AlloSure represents CareDx entry into the large kidney transplant surveillance diagnostic market. In the U.S. alone, there are more than 18,000 kidney transplants annually and an estimated 200,000 patients currently living with a transplanted kidney. There are approximately 10x the number of patients living with kidney transplants compared to those living with heart transplants, translating into an addressable market opportunity of greater than $2 billion annually
  • J
    GREAT Q and conference call, profitability second half of 2018...GLTA...

    47 Transplantation Centers Offering AlloSure
    9 Centers Enrolled in K-OAR
    BRISBANE, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the fourth quarter and full year ended December 31, 2017.
    Recent highlights:
    AlloSure commercially launched on October 9, 2017
    -- As of February 28, 2018, 47 U.S. transplant centers providing AlloSure testing to patients
    -- Continued progress in Kidney Allograft Outcomes AlloSure Registry (K-OAR) enrollment, with 9 centers initiated as clinical trial sites as of February 28, 2018
    Achieved total revenue for the fourth quarter 2017 of $12.5 million
    -- AlloSure® testing revenue of $0.5 million, representing 282 test results provided to kidney transplant patients
    -- AlloMap® testing revenue of $8.1 million, with fourth quarter US test volume increasing 8% year-over-year to 3,840 tests
    -- Product revenue of $3.7 million
    Revenue for the full year ended December 31, 2017 was $48.3 million, an increase of 19% year-over-year
    Announced refinancing of debt with Perceptive Advisors, to be completed in April 2018
    “The initial AlloSure interest and traction we experienced in the fourth quarter of 2017 continues in 2018,” said Peter Maag, CareDx President and Chief Executive Officer. “As of February 28, 2018, 47 centers are offering this high-value diagnostic test to kidney transplant patients across the US. Additionally, we enrolled our first patients and centers in the K-OAR registry and remain on-track to initiate 35 centers in this innovative study collecting longer-term outcome data on kidney transplant patients.”
    Maag added, “We believe our new and simplified capital structure positions CareDx to achieve its financial and operational goals going forward. I want to thank the entire CareDx team for our 2017 accomplishments and am looking forward to 2018 being another record year for the company. CareDx is well-positioned to become a leading provider of diagnostic solutions to the transplant community.”
  • W
    Outstanding management team...

  • E
    time to buy more share
  • t
    CDNA price target raised by Craig-Hallum from 35 to 40. Hopefully this link will post here from The Street dot Com. You'll see the article under "From our Partners" on the page...

    View detailed financial information, real-time news, videos, quotes and analysis on CareDx Inc. (NASDAQ:CDNA). Explore commentary on CareDx Inc. and hear what the experts at TheStreet are saying about CDNA
    View detailed financial information, real-time news, videos, quotes and analysis on CareDx Inc. (NASDAQ:CDNA). Explore commentary on CareDx Inc. and hear what the experts at TheStreet are saying about CDNA
  • Y
    Yahoo Finance Insights
    CareDx reached an all time high at 80.74
  • R
    Medical Services is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1
  • A
    Now we know why...

    Funds and institutions ENERGIING and taking new positions...

    Fred Alger Management Inc 1,238,351 4.30 New 0.04

    Perceptive Advisors LLC 1,040,676 3.61 New 0.25

    Gagnon Advisors, LLC 952,222 3.32 26,929.36 5.14

    Wellington Management Company LLP 928,200 3.22 New 0

    Stonepine Capital Management Llc 920,000 3.19 New 4.05

    Park West Asset Management LLC 809,793 2.81 New 0.27

    Emerald Mutual Fund Advisers Trust 500,000 1.73 New 0.15

    Midroc Invest AB, Co. 476,462 9.18 31.96 0

    FastPartner AB 424,184 8.17 31.97 0

    EAM Investors 373,896 1.30 New 0.36

    Vanguard Group Inc 371,610 2.38 117.63 0

    Next Century Growth Investors LLC 286,969 2.72 57.71 0.72

    Merckle International GmbH 226,915 4.18 23.41 0

    Private Wealth Partners, LLC 201,000 1.51 85.53 0.59

    Wexford Capital LP 200,000 0.69 New 0.13

    Granite Point Capital Management LP 190,000 0.66 New 0.14

    Royce & Associates, LLC 180,300 3.38 22.74 0.05

    Awm Investment Company Inc 175,000 0.61 New 0.25

    Friess Associates LLC 146,416 0.51 New 0.09

    Jacob Asset Management Of New York LLC 117,000 0.41 New 3.57

    Alger Small Cap Focus A 452,458 4.67 50.62 1.15

    Jacob Small Cap Growth Investor 75,667 0.26 New 3.61

    Alger Small Cap Growth I-2 68,698 0.58 68.76 0.49

    Royce Micro Cap Trust 56,000 0.19 New 0.11

    Vanguard Extended Market Idx Inv 55,300 0.99 23.86 0

    Alger Small Cap Growth B 43,540 0.37 69.17 0.49

    Jacob Micro Cap Growth Institutional 41,333 0.14 New 3.49

    AMG Managers Emerging Opps Svc 29,132 0.46 28.41 0.45

    BNY Mellon EB DL Mkt Completion 10,600 0.04 1,872.79 0

    Alger Small Cap Growth Institutional I 5,604 0.38 5.38 0.32

    BNY Mellon Market Completion Fund UC1 630 0 111.31 0

    Wells Fargo Dow Jones Target 2050 R6 22 0 3.91 0

    Wells Fargo Dow Jones Target 2040 A 7 0 0.70 0

    Wells Fargo Dow Jones Target 2055 R6 6 0 5.56 0

    Wells Fargo Dow Jones Target 2045 R6 3 0 0.87 0

    Wells Fargo Dow Jones Target Today A 2 0 3.85 0

    Wells Fargo Dow Jones Target 2060 A 2 0 7.14 0
  • W
    No news like great news...GLTA...

    The firm said it provided 1,051 AlloSure tests results to 842 patients, and 3,847 AlloMap heart transplant test results during the quarter. On a conference call with analysts following the release of the earnings, CareDx President and CEO Peter Maag said AlloSure is now being provided in 52 transplant centers in the US, which exceeds the firm's projections. He also noted that AlloMap testing volumes were negatively impacted by inclement weather in parts of the US in Q1, but added that volume growth was still within the firm's target range, and that CareDx remains focused on its strategy for patient adherence to testing protocols.

    Maag also said that revenues from CareDx's Olerup tissue typing products fell this quarter because of a decline in Olerup legacy products and a delay in 2017 in the development of the firm's new human leukocyte antigen (HLA) typing diagnostic Olerup QType. However, he added, the Qtype product received CE marking last month and is now available on the Roche LightCycler and Applied Biosystems' platforms. The firm is now scaling up manufacturing to meet demand from US and EU customers,